Ocuphire Pharma, Inc.: directors' dealings · United States · SEC (Form 4)

About Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States. Headquartered in Farmington Hills, Michigan, and founded in 2018, the company is focused on ophthalmology, with a development strategy built around small-molecule therapies for eye disorders with meaningful unmet medical need. For French-speaking investors, Ocuphire fits the profile of a clinical-stage micro/small-cap biotech: limited revenue visibility, high binary event risk, but potentially significant upside if clinical and regulatory milestones are achieved. The company’s core story revolves around two lead programs. The first is Nyxol® eye drops, a preservative-free ophthalmic solution of phentolamine mesylate designed for front-of-the-eye indications. Ocuphire has positioned Nyxol for multiple uses, including reversal of pharmacologically induced mydriasis, presbyopia, and dim light or night vision disturbances. The second major asset is APX3330, an oral tablet program aimed at pathways involved in retinal and choroidal vascular disease, particularly diabetic retinopathy and diabetic macular edema. This gives Ocuphire exposure to both anterior-segment and posterior-segment ophthalmic markets. From a competitive standpoint, Ocuphire operates in a crowded field dominated by larger pharmaceutical and ophthalmology companies with deeper balance sheets and more advanced commercial infrastructure. As a result, Ocuphire’s competitive advantage depends on clinical differentiation, ease of use, patient convenience, and the ability to progress programs into late-stage development and, ultimately, approval. The company does not yet have a broad commercial franchise, so its equity story remains primarily driven by pipeline execution rather than product sales. Recent corporate updates have continued to highlight development work on APX3330, particularly in non-proliferative diabetic retinopathy, alongside ongoing advancement of Nyxol across target indications. For investors, the key watchpoints are clinical readouts, regulatory interactions, funding needs, and any strategic partnerships that could help de-risk the pipeline or extend the company’s cash runway. In short, Ocuphire Pharma is a NASDAQ-listed ophthalmic biotech in the United States with a focused pipeline, a specialized niche, and a valuation profile that is highly sensitive to trial progress and FDA-related news.